Stock Evaluator: SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc. SLS

$17.95 -1.20 -6.27%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 35,637,407
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Commentary & Analysis


Financial Summary

Share Statistics SLS Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,659.3 $213.9 64%
Shares Out (Mil) 202.4 55.4 76%
Institutional Ownership 98.9% 93.3% 83%
Float (Mil) 203.1 40.6 74%
Beta 2.70 0.98 97%
Avg Daily Volume (000s) 21,025 597 98%
Price Change
(52-week)
1,173% 40.9% 100%
Growth SLS Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (9.9%) (10.7%) 29%
EPS (5yr) 34.9% 15.5% 85
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (31.5%) (15.7%) 18%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS ($0.050) ($0.200) ($0.245)
Month Ago EPS ($0.050) ($0.200) ($0.100)
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.050) ($0.200) ($0.100)
Year/Year Chg 0.0% (18.7%) (55.3%)
Financials SLS Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($36) ($44) 19%
EPS (TTM) ($0.203) ($1.400) 32%
Operating Cash Flow (TTM) (Mil) ($27) ($34) 13%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) $1,468 $135 46%
Valuation SLS Industry
Median
Percentile
(All Stocks)
P/B 27.62 1.97 97%
P/E na 17.6 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios SLS Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.8%) na
ROA (37.1%) (47.5%) 14%
ROE (40.3%) (51.9%) 17%
Liabilities to Assets 6.6% 29.7% 3%
F-Score 3 3 18%

SELLAS Life Sciences Group, Inc. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors